cd56-enriched donor lymphocyte
Cell therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 5, 2018 (NCT03524235)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetImmunity, passive
Immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03524235 | Phase 1 | Jul 5, 2018 | Cedars-Sinai Medical Center, Miltenyi Biotec, Inc., Teva |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cedars-Sinai Medical Center | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Miltenyi Biotec, Inc. | For profit | 1 | 0 | 1 | 2018 |
| Teva | For profit | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1